Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker BEFREE Biomarker analyses revealed O(6)-methylguanine-DNA methyltransferase-promoter methylation in 62.7% and wild-type isocitrate dehydrogenase in 97.5% of tumors. 31561040

2020

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker BEFREE Patients with MGMT methylated tumors (43%) had improved OS compared to those with unmethylated tumors; 7.03 vs 4.97 months (HR: 0.61, P-value: .027). 31756059

2020

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 AlteredExpression BEFREE In the carcinoid group, decreased MGMT gene expression was significantly associated with aggressive features (atypical histotype, grade G2, larger tumor size, higher T stage, and positive nodal status) but not with survival. 31280263

2020

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE MGMT gene promoter methylation status was determined on stored tumour samples using qMSP. 31701343

2020

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker BEFREE The main objective is to evaluate the value of tumor MGMT promoter (pMGMT) methylation in the prediction of the objective response (OR) at 3 months in patients treated with ALKY. 30824408

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 AlteredExpression BEFREE The current study aimed to examine the association between head and neck squamous cell carcinoma (HNSCC) and infection with different human papillomavirus virus (HPV) subtypes, including analysis of promoter methylation of several genes (APC, CDKN2A, MGMT, CDH1 and TIMP3) and the correlation with their mRNA expression in tumours and surgical margins. 30624179

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE Unfortunately, for glioblastoma multiforme (GBM), except for methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter that has some benefit in the local control of tumors using alkylating agents such as temozolomide, to date personalized treatments do not exist. 30504543

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker BEFREE Exploring this novel combined approach in the clinic to treat glioblastoma patients with MGMT promoter-unmethylated tumors is warranted. 30537486

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. 31366977

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE In recent years, there have been observations of patients changing their MGMT promoter methylation from primary tumor to relapse.Still, data on this topic are scarce. 31766430

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE Whether originating from astrocytes or oligodendrocytes, the high-grade gliomas with low FDG avidity represent a subgroup of high-grade gliomas presenting common characteristics: low aspartate, glutamate, and creatine levels, which are probably related to the impaired electron transport chain in mitochondria; high serine/glycine metabolism and so one-carbon metabolism; low glycerophosphocholine-phosphocholine ratio in membrane metabolism, which is associated with tumor aggressiveness; and finally negative MGMT methylation status. 31524681

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE We attempted to establish a magnetic resonance imaging (MRI)-based radiomic model for stratifying prognostic subgroups of newly diagnosed glioblastoma (GBM) patients and predicting O (6)-methylguanine-DNA methyltransferase promotor methylation (pMGMT-met) status of the tumor. 31594994

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE In conclusion, MGMT promoter methylation status and tumor location were identified as novel prognostic factors in adult PAs, pointing at distinct molecular subtypes and detecting patients in need of close observance and intensified treatment. 31362435

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 GeneticVariation BEFREE In GC cells, PGE<sub>2</sub> induced DNMT3B expression and activity, leading to increased methylated cytosine (5mC) and promoter methylation of tumor suppressive genes (MGMT and CNR1). 31534549

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 GeneticVariation BEFREE GPS and PSC may be associated with IDH1 mutation and MGMT gene promoter methylation status but not other glioma characteristics including tumor grade, location, or histopathology. 31141785

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 GeneticVariation BEFREE Archived tumour samples (N = 41) from three phase II TMZ trials carried out in MGMT-methylated mCRC (assessed by methylation-specific polymerase chain reaction [PCR]) were stratified by MGMT status as assessed by three different methods: mass spectrometry, PCR/methyl-BEAMing and RNA-seq. 30579113

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 AlteredExpression BEFREE MGMT gene expression level in MPC1 intact tumors was significantly lower than that in MPC1 deletion tumors (p = 0.0003). 31236818

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE Half of the tumors had MGMT promoter methylation (77, 52%). 30712777

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker BEFREE A meta-analysis was, therefore, conducted to assess whether tumor's MGMT promoter methylation status, isocitrate dehydrogenase (IDH) mutation status, volume, and extent of resection as well as patients' age at diagnosis and preoperative Karnofsky performance status score (KPS) correlate with SVZ contact by GBM. 29205011

2019

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker BEFREE Signals of activity in cohort 1 (n = 27) included partial (n = 6) and complete (n = 1) response, including in O<sup>6</sup>-methylguanine-DNA methyltransferase unmethylated and bevacizumab-refractory tumors. 29683790

2018

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE To examine the proportion of patients in NRG Oncology/RTOG 0424 with MGMT promoter methylation and its association with survival outcomes. 29955793

2018

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE The odds of having strong CD8 and CD68 reactivity was significantly less in MGMT methylated tumors. 29302887

2018

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 AlteredExpression BEFREE Three of five llgliomas with negative APTw features showed MGMT-negative immunostaining, leading to a negative predictive value of 60%, and 36 of 37 cases presenting positive APTw characteristics were tumors of MGMT-positive expression, generating a positive predictive value of 97.3%.The area under curve was 0.849. 29803064

2018

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 GeneticVariation BEFREE Eleven tumors (39.3%) showed MGMT methylation. 29103024

2018

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 PosttranslationalModification BEFREE Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. 29150792

2018